Close Menu

NEW YORK (GenomeWeb) – Biocept reported after the close of the market on Monday that its second quarter revenues increased 45 percent year over year.

For the three months ended June 30, the San Diego-based liquid biopsy firm saw $1.2 million in revenues compared to the $822,238 it brought in during the same quarter last year.

According to the company, revenue growth reflects a shift in commercial efforts toward specific segments of the oncology market where Biocept believes its assays can help the most patients: prostate, breast, and lung cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Department of Justice has proposed a rule change to enable DNA to be collected from migrants, the Associated Press reports.

Bernard Fisher, a surgeon who changed how breast cancer is treated, has died at 101, the New York Times reports.

Washington Post columnist writes that she is skeptical about DNA-based diets.

In PNAS this week: recurrent inactivation of DEPDC5 in gastrointestinal stromal tumors, taxonomic reliability of GenBank sequences, and more.